Successful treatment of Behçet's disease with lenalidomide [17]

British Journal of Dermatology

Volumn 158, Issue 1, 2008, Pages 197-198

  Green, J ^a   Upjohn, E ^a   McCormack, C ^a   Zeldis, J ^b   Prince, H M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b CELGENE CORPORATION   (United States)

Author keywords

Mouth ulceration; Therapeutics

Indexed keywords

AZATHIOPRINE; COLCHICINE; CYCLOSPORIN; DAPSONE; LENALIDOMIDE; PREDNISONE;

ADULT; ANAMNESIS; BEHCET DISEASE; CASE REPORT; CELL PROLIFERATION; DRUG POTENCY; HUMAN; LETTER; PRIORITY JOURNAL; T LYMPHOCYTE;

ADULT; BEHCET SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; MALE; ORAL ULCER; THALIDOMIDE;

EID: 36849010962     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.08288.x     Document Type: Letter

References (2)

1. Wechler B, for the International Study Group for Behçet's disease. Evaluation of diagnositic ('classification') criteria in Behçet's disease - towards internationally agreed criteria. Br J Rheumatol 1992 31 : 299 308.
2. Anderson KC. Lenalidomide and thalidomide: mechanisms of action - similarities and differences. Semin Hematol 2005 42 (4 Suppl. 4 S3 8.